David Bornstein
Acute Care · Rancho Mirage, CANPI 1609439892
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,257 of the $5,970 with a category attached, or 71.3%. 35 manufacturers reported payments, led by Novartis at 39.1% of the total. Reporting peaked in 2021 at $3,394 and has fallen 97.9% since, to $70 in 2025. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Pharmacyclics LLC, An Abbvie Company$335
- AstraZeneca$322
- Incyte Corporation$308
- Pfizer$267
- Lilly USA, LLC$261
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,25771%
- Education$992%
- Other$1,61527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 61 | $2,336 |
| Pharmacyclics LLC, An Abbvie Company | 17 | $335 |
| AstraZeneca(2 entities) | 18 | $322 |
| Incyte Corporation | 15 | $308 |
| Pfizer | 20 | $267 |
| Lilly USA, LLC | 19 | $261 |
| AbbVie | 8 | $183 |
| Bayer | 9 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $160 |
| Myovant Sciences Inc. | 9 | $145 |
| Bristol Myers Squibb | 6 | $134 |
| Eisai Inc. | 6 | $130 |
| AVEO Pharmaceuticals, Inc. | 5 | $112 |
| Merck | 5 | $99 |
| Karyopharm Therapeutics Inc. | 4 | $83 |
| Ipsen Biopharmaceuticals, Inc | 4 | $82 |
| Puma Biotechnology, Inc. | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 5 | $75 |
| Sobi, Inc | 3 | $72 |
| Amgen | 3 | $63 |
| Sanofi | 3 | $63 |
| Dova Pharmaceuticals | 3 | $61 |
| Astellas Pharma US Inc | 4 | $59 |
| Morphosys, US Inc. | 3 | $56 |
| Seagen Inc. | 3 | $53 |
| Beigene USA, Inc. | 2 | $40 |
| Servier Pharmaceuticals LLC | 2 | $39 |
| Array Biopharma Inc | 2 | $38 |
| Johnson & Johnson | 2 | $37 |
| EMD Serono, Inc. | 2 | $32 |
| Taiho Oncology, Inc. | 1 | $24 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $12 |
How this compares
$5,970 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lanreotide Acetate | 14 | $111,631 |
Paid to pharmacies, not to this prescriber.
Other acute care in Rancho Mirage
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.